Mahidol University's Institutional Repository
คลังสารสนเทศสถาบันของมหาวิทยาลัยมหิดล
"Wisdom Repository You Discover"
To collect Mahidol University's academic publications and intellectual properties more than 39 faculties
To present over 50,000 items of information in digital formats
To make it easy to access to all information at anytime, anywhere
Communities in Mahidol IR
Select a community to browse its collections.
Recent Submissions
Development and Validation of a Chinese Marital Intimacy Scale for Colorectal Cancer Survivors With an Ostomy (Ch-MIS-CRCO)
(2026-01-01) Du X.; Chaiviboontham S.; Sumdaengrit B.; Rattanasiri S.; Du X.; Mahidol University
Background: Marital intimacy plays a significant role in patients’ quality of life. However, colorectal cancer (CRC) and ostomy surgery can disrupt this important aspect of life. Despite its significance, there is no specialized tool to assess marital intimacy in this population. Therefore, this study aims to develop and validate the Chinese Marital Intimacy Scale for CRC survivors with an ostomy (CRCO) (Ch-MIS-CRCO). Methods: An observational cross-sectional study was conducted following the instrument development procedures outlined by DeVellis, which include instrument formation and psychometric testing phase. Content validity was evaluated by content validity index (CVI), while construct validity was examined by exploratory factor analysis (EFA) and confirmatory factor analysis (CFA). Convergent validity was assessed using correlations with the Lock and Wallace Marital Adjustment Test, Ostomy Adjustment Scale, and Stoma-QOL. Known-groups validity was evaluated across clinically relevant subgroups. Floor and ceiling effects were examined, and internal consistency reliability was assessed using Cronbach’s alpha. Results: The initial 52-item pool was refined through content validity assessment, pilot testing, item analysis, and EFA, resulting in a final 25-item scale across four dimensions, with eigenvalues ranging from 1.62 to 8.83, explaining 63.09% of the total variance. The scale demonstrated excellent model fit (χ2/df = 1.61; CFI = 0.95; TLI = 0.94; RMSEA = 0.05). Convergent validity was supported by significant correlations with the Lock and Wallace Marital Adjustment Test (r = 0.49), Ostomy Adjustment Scale (r = 0.55), and the Stoma-QOL (r = 0.59). Known-groups validity was confirmed, with higher scores observed among patients without ostomy complications, those with complete self-care ability, and those whose primary caregiver was their spouse (all p < 0.05). No floor or ceiling effects were detected. Internal consistency was high, with Cronbach’s α of 0.93 for the total scale and 0.85–0.90 for the subscales. Conclusion: The Ch-MIS-CRCO demonstrates strong psychometric properties and can be effectively used to evaluate marital intimacy among CRC survivors with an ostomy, further helping to predict and improve patients’ quality of life.
Baseline molecular surveillance of monkeypox virus virus in wildlife and exotic animals during the pre- and early-2022 outbreak in Thailand
(2026-01-01) Chamsai T.; Ketchim N.; Thongdee M.; Chaiwattanarungruengpaisan S.; Sariya L.; Kaewchot S.; Suwanpakdee S.; Paungpin W.; Chaisilp N.; Chamsai T.; Mahidol University
Background and Aim: The global outbreak of monkeypox (mpox) in 2022 raised major concerns regarding the potential establishment of new animal reservoirs outside endemic regions. Although human-to-human transmission was the primary driver of the outbreak, reverse zoonotic transmission (spillback) from infected humans to animals could lead to long-term viral persistence in wildlife populations. Thailand, a non-endemic country affected during the 2022 outbreak, has extensive human-animal interfaces involving free-ranging wildlife, exotic pets, and urban scavenging mammals, which may facilitate cross-species transmission. The present study aimed to perform molecular surveillance for mpox virus (MPXV) DNA in selected high-risk animal populations in Thailand using archival samples collected during the pre-outbreak (2019) and early-outbreak (2022) periods to establish baseline evidence of viral presence or absence. Materials and Methods: A total of 1,248 animals, including 593 free-ranging cynomolgus macaques (Macaca fascicularis), 436 exotic pets, and 219 garbage-scavenging small mammals, were included in this cross-sectional surveillance study. Swab samples (oral, nasal, buccal, or rectal) collected during 2019 and 2022 were retrieved from archival storage. Viral DNA was extracted using a commercial genomic DNA kit, and detection of MPXV was performed by real-time polymerase chain reaction targeting the B7R gene, a conserved region specific to MPXV. Samples were pooled in groups of 4–5 to increase screening efficiency. Descriptive statistics were used to determine prevalence, and the rule-of-three method and binomial probability model were applied to estimate confidence limits and surveillance power in the absence of positive results. Results: All 1,248 samples tested negative for MPXV DNA. The studied population represented 29 animal species across multiple ecological settings, including urban, peri-urban, and rural environments in several provinces of Thailand. Based on the sample size, the upper 95% confidence limit for prevalence was estimated to be <0.24%. Power analysis indicated a 99.81% probability of detecting at least one positive case if the true prevalence had been ≥0.5%, confirming strong surveillance sensitivity. Conclusion: This study provides the first ecological baseline evidence of the absence of MPXV in wildlife, exotic pets, and garbage-scavenging mammals in Thailand before and during the early phase of the 2022 global outbreak. The findings support the importance of One Health-based surveillance integrating wildlife, domestic animals, and environmental interfaces to prevent spillback events and the establishment of new reservoirs in non-endemic regions. Continued longitudinal monitoring using both molecular and serological approaches is essential for early detection of emerging zoonotic threats.
Retraction notice to "Recent advancements of nanoparticles application in cancer and neurodegenerative disorders: At a glance"(Biomedicine & Pharmacotherapy, (2022), 153, C, (113305), (S0753332222006941), 10.1016/j.biopha.2022.113305)
(2026-01-01) Rahman M.M.; Islam M.R.; Akash S.; Harun-Or-Rashid M.; Ray T.K.; Rahaman M.S.; Islam M.; Anika F.; Hosain M.K.; Aovi F.I.; Hemeg H.A.; Rauf A.; Wilairatana P.; Rahman M.M.; Mahidol University
This article has been retracted: please see Elsevier Policy on Article Correction, Retraction and Removal (https://www.elsevier.com/about/policies/article-withdrawal). This article has been retracted at the request of the Editor. Post-publication, an investigation conducted by Elsevier's Research Integrity & Publishing Ethics team on behalf of the journal identified references that are irrelevant to the article. The authors were asked to comment upon the presence of these references in their work but were unable to satisfactorily address the reason for the references. Consequently, the editor has lost confidence in the results and conclusions of the article and has determined it should be retracted. Apologies are offered to readers of the journal that this was not detected during the submission process. The authors disagree with retraction and dispute the grounds for it
Transdermal delivery of pramipexole dihydrochloride using dissolving polymeric microneedle patches for improved Parkinson's disease management
(2026-06-01) Thamphiwatana S.D.; Phetporkha K.; Thedrattanawong C.; Chantasart D.; Thamphiwatana S.D.; Mahidol University
Parkinson's disease (PD) is a progressive neurodegenerative disorder commonly treated with oral pramipexole dihydrochloride monohydrate (PXCl), a dopamine agonist. Oral therapy is often limited by gastrointestinal complications, variable absorption, and poor patient adherence, highlighting the need for alternative delivery strategies. Dissolving microneedles (MNs) offer a minimally invasive, patient-friendly platform for transdermal drug delivery, enabling sustained and controlled release. In this study, PXCl-loaded MNs were developed using three polymer blends: polymethyl-vinyl-ether- co -maleic acid/polyvinyl alcohol (PMVEMA-PVA30K), carboxymethylcellulose sodium/polyvinyl alcohol (CMC-PVA30K), and polyvinylpyrrolidone/polyvinyl alcohol (PVP-PVA70K). Micro-molding produced MNs with sharp, uniform geometries, and adequate mechanical strength to penetrate the skin, achieving insertion efficiencies above 94%. Fourier-transform infrared spectroscopy confirmed intermolecular hydrogen bonding and ionic interactions between PXCl and the polymer matrices. In vitro release studies across cellulose membranes demonstrated complete PXCl release within 48–72 h, with faster release from CMC- and PVP-based MNs. Notably, PMVEMA-PVA30K MNs, despite slower release, showed the highest PXCl permeation and flux across full-thickness human skin, likely due to stronger drug-polymer interactions, enhanced MN rigidity, and polymer-induced modulation of skin permeability. Biocompatibility assays indicated that all formulations were non-hemolytic and non-cytotoxic. These findings demonstrate that dissolving MNs provide a promising strategy for transdermal PXCl delivery and suggest that PMVEMA-PVA30K matrices may offer an effective, sustained therapeutic approach for PD treatment.
The Success Paradox: Thailand's dialysis policy evolution and implications for modality choice reforms
(2026-01-01) Boongird S.; Kanjanabuch T.; Phannajit J.; Chuengsaman P.; Thammatacharee J.; Ophascharoensuk V.; Boongird S.; Mahidol University
Thailand's peritoneal dialysis (PD) policy evolution illustrates how apparent policy success can mask underlying system vulnerabilities. Between 2008 and 2021, Thailand's PD-First policy under the Universal Coverage Scheme (UCS) became an international model, expanding PD utilization from 2760 to over 25,000 patients while maintaining outcomes comparable to global benchmarks. In February 2022, the 2022 Policy removed PD-First restrictions to enhance patient choice. Within 3 years, PD utilization among incident UCS patients declined from 50% to 14%, 90-day mortality risk rose from 9% to 13%, and dialysis expenditures increased to 12% of the total UCS budget. These outcomes prompted the 2025 Reform in April 2025, following a review commissioned by the National Health Security Office and conducted by the Health Intervention and Technology Assessment Program (HITAP), with expert input from the Nephrology Society of Thailand (NST) and other stakeholders. Using aggregated national registry data across three periods—the PD-First period (2008–2021), the 2022 Policy period (2022–2024), and the 2025 Reform period (2025)—we examined utilization patterns, clinical outcomes, and fiscal impacts associated with these transitions. The temporal patterns suggest that rapid policy liberalization may expose and amplify existing capacity imbalances. Following the 2022 transition, utilization shifted toward existing hemodialysis infrastructure despite inadequate vascular surgery capacity, coinciding with reduced rates of permanent access and increased early mortality. Preliminary post-reform data show encouraging recovery, with 90-day mortality risk falling to 7%. Thailand's experience may inform countries expanding home dialysis through policy reforms, highlighting that sustainable choice requires sequenced policy liberalization, infrastructure capacity alignment, and responsive governance to maintain dialysis quality, equity, and fiscal stability.